Banning drugs from NHS stifles new development, drug company saysBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b1295 (Published 27 March 2009) Cite this as: BMJ 2009;338:b1295
- Oona Mashta
Drug companies are increasingly reluctant to invest money in the research and development of innovative drugs because of fears that their costs might not be met if the drugs were not approved by the National Institute for Health and Clinical Excellence (NICE), according to a drugs expert.
Jon Pender, from GlaxoSmithKline’s government affairs department, said that drug companies were not being rewarded for benefits drugs bring to health, which is stifling creativity because the emphasis is all on cost.
He was speaking during the 2009 Bupa health debate on drug pricing, shown live around …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial